Antithrombotic Treatment of Stable Coronary Artery Disease.
Antithrombotics
Coronary artery disease
Dual antiplatelet therapy
Dual pathway inhibition
Journal
Acta Cardiologica Sinica
ISSN: 1011-6842
Titre abrégé: Acta Cardiol Sin
Pays: China (Republic : 1949- )
ID NLM: 101687085
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
08
12
2020
accepted:
13
05
2021
entrez:
23
11
2021
pubmed:
24
11
2021
medline:
24
11
2021
Statut:
ppublish
Résumé
Coronary artery disease (CAD) is one of the leading causes of death in Taiwan. Despite the use of current guideline-recommended therapies for secondary prevention, the residual risk of recurrent cardiovascular events remains high in CAD, warranting the need for new treatment options. Antithrombotic drugs are one of the most important medical therapies for CAD. In this article, we review the unmet needs of the current antithrombotic agents and summarize the results of clinical trials with dual antiplatelet therapy in stable CAD. We also review data from a recent study demonstrating the benefits of a dual pathway inhibition strategy with antiplatelet and anticoagulant therapy, a new option for CAD treatment. Finally, we propose a treatment algorithm for choosing different antithrombotic regimens for CAD based on current scientific evidence and expert opinions.
Identifiants
pubmed: 34812230
doi: 10.6515/ACS.202111_37(6).20210513A
pmc: PMC8593487
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
574-579Références
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
N Engl J Med. 2019 Oct 3;381(14):1309-1320
pubmed: 31475798
Eur Heart J Acute Cardiovasc Care. 2019 Oct;8(7):634-642
pubmed: 28895425
Clin Cardiol. 2016 Nov;39(11):670-677
pubmed: 27588731
J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115
pubmed: 27036918
Lancet. 1996 Nov 16;348(9038):1329-39
pubmed: 8918275
Lancet. 2017 Mar 11;389(10073):1025-1034
pubmed: 28290994
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
Thromb Haemost. 2014 Nov;112(5):924-31
pubmed: 25030773
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
J Am Coll Cardiol. 2016 Jun 14;67(23):2719-2728
pubmed: 27046162
J Am Coll Cardiol. 2007 May 15;49(19):1982-8
pubmed: 17498584
Circ J. 2020 Apr 24;84(5):831-865
pubmed: 32173684
J Am Coll Cardiol. 2012 Dec 18;60(24):e44-e164
pubmed: 23182125
N Engl J Med. 2017 Jan 5;376(1):32-40
pubmed: 27959717
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
J Am Coll Cardiol. 2019 Jul 2;73(25):3271-3280
pubmed: 31248548
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
JAMA. 2010 Sep 22;304(12):1350-7
pubmed: 20805624
Lancet. 2018 Jan 20;391(10117):205-218
pubmed: 29132879
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
N Engl J Med. 2014 Dec 4;371(23):2155-66
pubmed: 25399658
Curr Probl Cardiol. 2010 Feb;35(2):72-115
pubmed: 20109979
Can J Cardiol. 2014 Aug;30(8):837-49
pubmed: 25064578
N Engl J Med. 2015 May 7;372(19):1791-800
pubmed: 25773268
Ann Transl Med. 2016 Jul;4(13):256
pubmed: 27500157
Eur Heart J. 2016 Apr 7;37(14):1133-42
pubmed: 26491109
JAMA. 2016 Apr 26;315(16):1735-49
pubmed: 27022822